The Genedrive share price is falling so here’s what I’m doing now

Jabran Khan explores why the Genedrive share price has fallen since yesterday morning. Is this stock an opportunity or one to avoid?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One stock that I noticed fall in price substantially yesterday is Genedrive (LSE:GDR). The Genedrive share price is down almost 30% after it announced half-year results.

Genedrive is a molecular diagnostics firm that develops and commercialises low cost, rapid, versatile, simple to use molecular diagnostics platforms for the diagnosis of infectious diseases. These are used in patient stratification. Its developments have been validated and launched in Africa and the Asia Pacific region. It also has distribution agreements for the use of its platforms in EMEA.

The Genedrive share price

The past 12 months have been a roller-coaster ride for the Genedrive share price. Just over a year ago today, it was trading for less than 25p per share. At the time of the market crash, its shares were up to 220p, which is a five-year high. As I write, I can purchase shares for less than 70p per share. At the beginning of trading yesterday, the Genedrive share price was over 115p.

Since that point, however, things have been quite up and down. I do believe Genedrive is a stock which has potential and with its recent slump and past highs, there may be an opportunity to add it to my portfolio cheaply.

Upon reviewing its results for the six months to 31 December, I must admit I was disappointed. I believe this is the reason the Genedrive share price has dropped off since the results were announced yesterday.

Half-year results

Genedrive reported total revenues of £400,000 for the six-month period. This is down from £600,00 compared to the same period last year. As a result, its operating loss rose to £2.9m from £2.6m which is disappointing. As of 15 March, cash stood at just less than £3m. There was an R&D tax credit of £1m still outstanding too.

Genedrive’s results were in part due to delays and the pandemic affecting sales. A prime example of this was a contract with the US Department of Defense stalling somewhat that has suppressed progress in what could have been extremely lucrative. Further impact of the Covid-19 pandemic relates to Genedrive’s Covid-19 testing kit. Progress has slowed down as it awaits regulatory approval from the World Health Organization (WHO) and the US Food and Drug Administration (FDA).

As well as less than stellar results, these other aspects have weighed on the Genedrive share price in recent times in my opinion.

What I’m doing now

I must note there are positives to take from its recent update. The firm is now debt-free which is always an attractive trait for any company. In addition, there are commercial contracts in which Genedrive is involved that are producing results. There is a distribution agreement with Beckman Coulter Life Sciences as well as an opportunity with the European Ministry of Health that could bring in millions in revenue.

Overall I am not tempted by the falling Genedrive share price. I will keep an eye on developments, however. Right now, I won’t be investing my hard-earned cash. I am look at other alternatives such as this FTSE 100 stock, which I believe could be a great opportunity.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This FTSE sell-off gives me an unmissable chance to buy cut-price UK stocks!

The last few months have been tough for UK stocks and their troubles aren't over yet, but Harvey Jones isn't…

Read more »

Investing Articles

Here’s the forecast for the Tesla share price as Trump’s policies take focus

The Tesla share price surged following Donald Trump’s election victory, but the stock is trading far above analysts’ targets. Dr…

Read more »

Investing Articles

£15,000 in cash? I’d pick growth stocks like these for life-changing passive income

Millions of us invest for passive income. Here, Dr James Fox explains his recipe for success by focusing on high-potential…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s my plan for long-term passive income

On the lookout for passive income stocks to buy, Stephen Wright is turning to one of Warren Buffett’s most famous…

Read more »

artificial intelligence investing algorithms
Growth Shares

Are British stock market investors missing out on the tech revolution?

British stock market investors continue to pile into ‘old-economy’ stocks. Is this a mistake in today’s increasingly digital world?

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

My 2 best US growth stocks to buy in November

I’ve just bought two US growth companies on my best stocks to buy now list, and I think they’re still…

Read more »

Investing Articles

£2k in savings? Here’s how I’d invest that to target a passive income of £4,629 a year

Harvey Jones examines how investing a modest sum like £2,000 and leaving it to grow for years can generate an…

Read more »

Renewable energies concept collage
Investing Articles

Down 20%! A sinking dividend stock to buy for passive income?

This dividend stock is spending £50m buying back its own shares while they trade at a discount and also planning…

Read more »